Eli Lilly and Company
Eli Lilly and Company, commonly referred to as Lilly, is a global leader in the pharmaceutical industry, headquartered in the United Kingdom. Founded in 1876, the company has established a strong presence in major operational regions, including North America, Europe, and Asia, focusing on innovative solutions in diabetes, oncology, immunology, and neuroscience. Lilly is renowned for its pioneering products, such as insulin therapies and cancer treatments, which are distinguished by their commitment to research and development. The company has achieved significant milestones, including the introduction of groundbreaking medications that have transformed patient care. With a robust market position, Eli Lilly continues to be recognised for its contributions to healthcare, consistently ranking among the top pharmaceutical companies worldwide.
DitchCarbon Score
How does Eli Lilly and Company's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eli Lilly and Company's score of 56 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eli Lilly and Company's reported carbon emissions
In 2024, Eli Lilly and Company reported total greenhouse gas emissions of approximately 192,000,000 kg CO2e for Scope 1 and about 258,000,000 kg CO2e for Scope 2 (market-based). This brings their combined Scope 1 and 2 emissions to around 450,000,000 kg CO2e. In 2023, the company recorded Scope 1 emissions of about 182,000,000 kg CO2e and Scope 2 emissions of approximately 345,000,000 kg CO2e (market-based), resulting in a total of about 527,000,000 kg CO2e for both scopes. Eli Lilly has made significant strides in reducing its carbon footprint, achieving a 26% absolute emissions reduction in its operations from 2020 to 2023. This reduction encompasses both Scope 1 and Scope 2 emissions, despite the company's growth during this period. Furthermore, they are committed to becoming carbon neutral in their own operations (Scope 1 and 2) by 2030, which aligns with their broader climate strategy. The company has not disclosed Scope 3 emissions data for 2024, but in 2023, it reported approximately 5,139,500,000 kg CO2e in Scope 3 emissions, indicating a substantial area for potential improvement in their value chain emissions reporting. Eli Lilly's climate commitments reflect a proactive approach to sustainability, with a focus on transparency and accountability in emissions reporting, as well as a clear target for future reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2012 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 220,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | 266,000,000 | 000,000,000 | 000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eli Lilly and Company is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
